The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of irinotecan plus cisplatin versus irinotecan alone after S-1 based chemotherapy failure for patients with advanced and recurrent gastric cancer (AGC) (TCOG GI-0801).
Ken Shimada
No relevant relationships to disclose
Katsuhiko Higuchi
No relevant relationships to disclose
Naoshi Hosaka
No relevant relationships to disclose
Eisaku Sasaki
No relevant relationships to disclose
Norisuke Nakayama
No relevant relationships to disclose
Kenji Amagai
No relevant relationships to disclose
Yuiti Takeda
No relevant relationships to disclose
Toshikazu Moriwaki
No relevant relationships to disclose
Takashi Sekikawa
No relevant relationships to disclose
Toshikazu Sakuyama
No relevant relationships to disclose
Kazuhito Yajima
No relevant relationships to disclose
Satoshi Tanabe
No relevant relationships to disclose
Yusuke Saito
No relevant relationships to disclose
Yoshiharu Maeda
No relevant relationships to disclose
Ken Nishimura
No relevant relationships to disclose
Tohru Sasaki
No relevant relationships to disclose
Kouji Kobayashi
No relevant relationships to disclose
Tatsu Shimoyama
No relevant relationships to disclose
Ichinosuke Hyodo
No relevant relationships to disclose
Wasaburo Koizumi
No relevant relationships to disclose